Inhibition of MDR1 overcomes resistance to brentuximab vedotin in Hodgkin lymphoma
2019
Purpose: In classical Hodgkin lymphoma (HL), the malignant Reed-Sternberg cells express the cell surface marker CD30. Brentuximab vedotin (BV) is an antibody-drug conjugate that selectively delivers a potent cytotoxic agent, monomethyl auristatin E (MMAE), to CD30-positive cells. Although BV elicits a high response rate (75%) in relapsed/refractory HL, most patients who respond to BV eventually develop resistance. Experimental Design: We developed two BV-resistant HL cell line models using a pulsatile approach and observed that resistance to BV is associated with an upregulation of multidrug resistance-1 (MDR1). We then conducted a phase 1 trial combining BV and cyclosporine A (CsA) in patients with relapsed/refractory HL. Results: Here, we show that competitive inhibition of MDR1 restored sensitivity to BV in our BV-resistant cell lines by increasing intracellular MMAE levels, and potentiated BV activity in BV-resistant HL tumors in a human xenograft mouse model. In our phase 1 trial, the combination of BV and CsA was tolerable and produced an overall and complete response rate of 75% and 42% in a population of patients who were nearly all refractory to BV. Conclusions: This study may provide a new therapeutic strategy to combat BV resistance in HL. This is the first study reporting an effect of multidrug resistance modulation on the therapeutic activity of an antibody-drug conjugate in humans. The expansion phase of the trial is ongoing and enrolling patients who are refractory to BV to confirm clinical activity in this population with unmet need.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
43
References
22
Citations
NaN
KQI